Skip to main content
. Author manuscript; available in PMC: 2022 Nov 19.
Published in final edited form as: Transplant Cell Ther. 2022 Aug 5;28(11):760.e1–760.e5. doi: 10.1016/j.jtct.2022.07.030

Table 1.

Percent conversion to MRD− CR post-ASCT by IMWG response achieved pre-ASCT

Pre-ASCT IMWG response N (%) Post-ASCT MRD(−) CR, N (%)
MF-CR MRD(−) 23 (11) 21 (91)**
MF-CR MRD(+) 27 (14) 21 (78)
MF-VGPR MRD(−) 20 (11) 6 (30)
MF-VGPR MRD(+) 65 (35) 13 (20)
PR 59 (32) 4 (7)
MR 12 (6) 1 (8)
SD 4 (1) 0 (0)
*

Percent(%) in column 3 represents proportion of patients converting in each category (row)

**

Two patients lost MRD negative status after ASCT but remained in CR